0
Lung Cancer |

Five Year Lung Cancer Survival (2004-2007) From Hospital Virgen de las Nieves in Granada

Rosa Maria Ortiz Comino, MD; Noemi Burgos Guadix, MD; Rosa Lina De los Santos de Lopez, MD; Ana Dolores Romero Ortiz, PhD; Manuel De Vega, PhD
Author and Funding Information

Hospital Virgen de las Nieves, Granada, Spain


Chest. 2014;145(3_MeetingAbstracts):327A. doi:10.1378/chest.1822395
Text Size: A A A
Published online

Abstract

SESSION TITLE: Lung Cancer Posters II

SESSION TYPE: Poster Presentations

PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM

PURPOSE: Lung cancer remains the leading cause of cancer deaths wordlwide. There is a limited data evaluating overall five years lung cancer survival. The aim of this study is to describe the characteristics of our patients with lung cancer and the five years survival rate in our hospital.

METHODS: This is a retrospective analysis of all patients who had lung cancer from Jan 2004 to Dec 2007 at Hospital Virgen de las Nieves in Granada. Data collected included baseline demographics, diagnosis, staging, treatment and mortality.

RESULTS: Three hundred sixty six patients (87,98% male, mean age 65.77) were diagnosed of lung cancer of which 93.44% were or had been smoker (79,23% active-smoker). The most common histology was squasmous cell (41,80%) follow by undifferenttiated non-small cell (24,86%), small cell (19.13%) and adenocarcinoma (14.21%). In non-small cell (NSC) staging was distributed as: I and II 10,39%, IIIA 11,75%, IIIB 17.76% and IV 35,25%. Therefore, regional (III) and distant (IV) stages were the most common (64,76%).So that, treatment distribution was quimiotherapy (QT) and radiotherapy (RT) n=122, QT n=104, Paliative care n= 95, Surgery n=32, RT n=13. Overall five years survival was 3.55% (3.24% male, 7.14% female). Five years survival by histology: Squasmous cell 5.52%, Adenocarcinoma 6%, Indifferentiated NSC 0%, Small-cell 2.9%. Five years NSC survival by stage: Local (I-II) 5.52%, Regional (III) 1.92%, Distant (IV) 0%. Five years survival by treatment: Surgery n=9 (NSC n=9), QT and RT n=3 (NSC n=1, small-cell n=2). The different at treatment survival are significantly different. There was no five year survival with other treatments.

CONCLUSIONS: In the period 2004-2007 we diagnosed more squamous cell than adenocarcinoma and the most of our patients were men. At diagnosis many patients were at advanced stage with no option for surgery treatment which implied poorer prognosis. The overall survival in our hospital is smaller than worldwide stadistics publish by SEER.

CLINICAL IMPLICATIONS: It would be necessary to diagnose lung cancer at earlier stages in order to improve survival.

DISCLOSURE: The following authors have nothing to disclose: Rosa Maria Ortiz Comino, Noemi Burgos Guadix, Rosa Lina De los Santos de Lopez, Ana Dolores Romero Ortiz, Manuel De Vega

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543